In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s shares closed last Friday at $67.73.
According to TipRanks, Biegelsen is a 5-star analyst with an average return of 12.3% and a 62.28% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Abbott Labs, and Boston Scientific.
Axonics Modulation Technologies has an analyst consensus of Hold, with a price target consensus of $71.00, which is a 4.83% upside from current levels. In a report released on February 28, RBC Capital also maintained a Hold rating on the stock with a $71.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $69.68 and a one-year low of $47.59. Currently, Axonics Modulation Technologies has an average volume of 1.26M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axonics Modulation Technologies (AXNX) Company Description:
Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.
Read More on AXNX:
